NCT06360965 Clinical Trial of Acupoint Application in Improving the Sequelae of Pelvic Inflammatory Disease and Chronic Pelvic Pain
| NCT ID | NCT06360965 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Hospital of Integrated Traditional Chinese and Western Medicine |
| Condition | Pelvic Inflammatory Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 102 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2026-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 102 participants in total. It began in 2024-01-01 with a primary completion date of 2026-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Chronic Pelvic Pain is one of the common gynecological symptoms, characterized by persistent and non periodic pain in the pelvic cavity and surrounding tissues. It is often seen as a sequelae of pelvic inflammatory diseases caused by the failure to receive timely and correct treatment. This study compares the effectiveness of warm meridians and relieve pain plaster in relieving the sequelae of pelvic inflammatory disease and chronic pelvic pain symptoms, and evaluates the safety of improved patches and traditional patches, further promoting it to community grassroots hospitals.
Eligibility Criteria
Inclusion Criteria: 1. Meets the diagnostic criteria of traditional Chinese and Western medicine for sequelae of pelvic inflammatory disease and chronic pelvic pain; 2. Transvaginal ultrasound examination shows thickening of the fallopian tube wall and fluid accumulation in the lumen, which may be accompanied by pelvic free fluid or fallopian tube ovarian masses; 3. The age range is 18-50 years old, married or with a history of sexual activity; 4. Those with a menstrual cycle of 21-35 days; 5. 4 points ≤ Pain Visual Analog Scale (VAS) \< 7 points; 6. Those who have signed an informed consent form and are willing to receive treatment. Exclusion Criteria: 1. Female patients who have fertility requirements during pregnancy, lactation, or in the short term; 2. Patients with gynecological diseases such as organic lesions of the reproductive system or gynecological acute abdomen; 3. Chronic pelvic pain caused by gynecological tumors, endometriosis, pelvic congestion syndrome, uterine fibroids, tuberculous pelvic inflammatory disease, and other diseases confirmed through examination; 4. Those with severe diseases such as cardiovascular, cerebrovascular, liver and kidney function, and digestive system; 5. Individuals with mental abnormalities and psychological disorders; 6. Individuals with allergic constitution or known allergies to the drugs and their components used in this experiment; 7. Patients currently participating in clinical trials of other drugs; 8. Other methods of treatment have already been or are currently being carried out, which may affect the indicators observed in this study.
Contact & Investigator
Yu Cao, Master
PRINCIPAL INVESTIGATOR
Beijing Hospital of Integrated Traditional Chinese and Western Medicine
Frequently Asked Questions
Who can join the NCT06360965 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 50 Years, studying Pelvic Inflammatory Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06360965 currently recruiting?
Yes, NCT06360965 is actively recruiting participants. Contact the research team at howgreenbreeze@126.com for enrollment information.
Where is the NCT06360965 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06360965 clinical trial?
NCT06360965 is sponsored by Beijing Hospital of Integrated Traditional Chinese and Western Medicine. The principal investigator is Yu Cao, Master at Beijing Hospital of Integrated Traditional Chinese and Western Medicine. The trial plans to enroll 102 participants.